Skip to main content

Table 3 Costs associated with the management of adverse events

From: Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

  Unit cost Pazopanib Sunitinib Cost difference
Adverse event Value Reference Incidence Per patient cost Incidence Per patient cost  
Anorexia   [28]   €4.97   €4.97 €0.00
Grades I and II €13.43   36%   34%   
Grade III €13.43   1%   3%   
Diarrhea   [28]   €127.12   €161.01 -€33.89
Grades I and II €6.05   54%   49%   
Grade III €1,376.13   9%   7%   
Grade IV €6,171.42     1%   
Fatigue   [28]   €0.89   €1.02 -€0.13
Grades I and II €1.62   44%   45%   
Grade III €1.62   10%   17%   
Grade IV €1.62   1%   1%   
Hand-foot syndrome   [29]   €23.30   €52.20 -€28.90
Grades I and II €51.87   23%   38%   
Grade III €189.41   6%   11%   
Grade IV €1,165.50     1%   
Hypertension   Expert judgment   €33.72   €32.88 €0.84
Grades I and II €16.88   30%   25%   
Grade III €16.88   15%   15%   
Grade IV €2,612.71   1%   1%   
Nausea   [28]   €52.28   €52.59 -€0.31
Grades I and II €31.24   43%   44%   
Grade III €1,942.30   2%   2%   
Laboratory abnormality        
Anemia   [28]   €65.77   €126.91 -€61.14
Grades I and II €200.26   29%   53%   
Grade III €261.70   1%   6%   
Grade IV €507.46   1%   1%   
ALT   Expert judgment   €136.70   €79.77 €56.93
Grades I and II €119.30   43%   38%   
Grade III €236.16   15%   4%   
Grade IV €2,498.64   2%   1%   
Neutropenia   [28]   €138.00   €248.60 -€110.60
Grades I and II €356.78   32%   48%   
Grade III €356.78   4%   19%   
Grade IV €955.53   1%   1%   
Trombocitopenia   [28]   €78.83   €214.13 -€135.30
Grades I and II €139.29   37%   56%   
Grade III €449.54   3%   18%   
Grade IV €1,380.29   1%   4%   
Total     €661.58   €974.08 -€312.50